CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney...
Phase 3
Birmingham, Alabama, United States and 12 other locations
to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney...
Phase 3
Irondale, Alabama, United States and 338 other locations
Primary Objective:Evaluate the effect of Hectorol® capsules in reducing elevated levels of intact parathyroid hormone (iPTH).Secondary Objectives:* E...
Phase 3
Birmingham, Alabama, United States and 29 other locations
CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 (also known as pacibekitug) in participants with chronic kidney...
Phase 2
Birmingham, Alabama, United States and 41 other locations
tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney...
Phase 2, Phase 3
Birmingham, Alabama, United States and 282 other locations
(for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation.Parti...
Phase 3
Birmingham, Alabama, United States and 950 other locations
and adolescent participants with anemia associated with chronic kidney disease (CKD) incorporating 2 independent sub-trials (Non di...
Phase 3
Birmingham, Alabama, United States and 19 other locations
of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/ ...
Phase 3
Birmingham, Alabama, United States of America and 707 other locations
The ASSIST study is a phase 2, double-blind, placebo-controlled crossover study to evaluate the safety and efficacy of atrasentan vs. placebo in subj...
Phase 2
Birmingham, Alabama, United States and 29 other locations
The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA...
Phase 3
Birmingham, Alabama, United States and 135 other locations
Clinical trials
Research sites
Resources
Legal